Table 2 COVID-19 hospitalization and mortality rates in female patients treated with a single hormone therapy in Emilia-Romagna region. Data were collected from January 1 st to December 31 st, 2020 and compared to the regional risks. Statistically significant values are indicated in bold. The logistic model applied is described in the Methods. SHR, standard hospitalization ratio; SMR, standard mortality ratio; 90% CI, 90% confidence interval; Exp., expected number of cases; CDK, cyclin-dependent kinase.
Therapies | COVID-19 hospitalization | COVID-19 mortality | ||||||
|---|---|---|---|---|---|---|---|---|
SHR | 90% CI | Exp. | COVID-19 hospitalized (%) | SMR | 90% CI | Exp. | COVID-19 deaths (%) | |
Tamoxifen | 1.26 | 0.88–1.76 | 21 | 26 (0.58) | 0.21 | 0.01–0.98 | 5 | 1 (0.02) |
Aromatase inhibitors | 1.36 | 1.21–1.52 | 151 | 205 (1.19) | 0.96 | 0.75–1.23 | 52 | 50 (0.29) |
Fulvestrant (± CDK4/6 inhibitors) | 1.74 | 0.91–2.31 | 5 | 9 (1.84) | 1.52 | 0.41–3.92 | 2 | 3 (0.61) |
Breast cancer cohort | 1.36 | 1.22–1.51 | 176 | 240 (1.08) | 0.92 | 0.72–1.15 | 59 | 54 (0.24) |
